Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium valproate added to 3+7 induction chemotherapy for adults with non-M3 acute myeloid leukemia
IRCT20240923063132N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of valproic acid in acute myeloid leukemia (AML) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Time to complete remission, Absolute neutrophil count change and 3 more. Started Aug 2024; status: completed.
02
Drugs
valproic acid
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on IRCT20240923063132N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240923063132N1.